Corcept Therapeutics Faces Class Action for Disclosure Failures
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy CORT?
Source: Globenewswire
- Lawsuit Background: Corcept Therapeutics is facing a securities class action lawsuit for failing to disclose material information during the period from October 31, 2024, to December 30, 2025, with investors required to file lead plaintiff applications by April 21, 2026, to seek recovery for economic losses.
- FDA Response Letter: During the class period, Corcept assured investors of a high likelihood of FDA approval for its new drug application; however, on December 31, 2025, it received a Complete Response Letter from the FDA, necessitating additional evidence of effectiveness, which led to a significant drop in stock price.
- Stock Price Impact: Following the FDA's response, Corcept's stock plummeted by 50.4%, from $70.20 on December 30, 2025, to $34.80, representing a loss of $35.40 per share, indicating severe market pessimism regarding the company's future prospects.
- Legal Consultation Opportunity: Investors seeking to understand their legal rights and the potential impact of this case on their economic losses can contact Kahn Swick & Foti for a free consultation, assisting them in navigating the lawsuit process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 46.160
Low
50.00
Averages
91.00
High
121.00
Current: 46.160
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CORT Investors Urged to Act Before April 21 Deadline in Class Action
- Critical Deadline: Hagens Berman reminds investors in Corcept Therapeutics (NASDAQ:CORT) that the deadline to apply as Lead Plaintiff in the securities class action for losses incurred between October 31, 2024, and December 30, 2025, is April 21, 2026, urging prompt submission of loss information to safeguard their rights.
- Allegations Overview: The lawsuit alleges that Corcept concealed significant information regarding its lead drug candidate, relacorilant, as the company publicly emphasized its potential approval while failing to disclose management's private expectations of failure, misleading investors in the process.
- Information Gap: Reed Kathrein, a partner at Hagens Berman, highlighted that the case reveals a
See More
Corcept Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Corcept in the Northern District of California on behalf of investors who purchased shares between October 31, 2024, and December 30, 2025, highlighting significant legal risks and potential liabilities for the company.
- FDA Approval Risks: The lawsuit alleges that Corcept misrepresented the clinical trial results of relacorilant, claiming it provided “powerful support” for FDA approval, while in reality, the FDA raised concerns about the adequacy of clinical evidence, which could undermine the company's credibility and shareholder confidence.
- Stock Price Plunge: Following the announcement of a Complete Response Letter from the FDA on December 31, 2025, Corcept's stock price plummeted from $70.20 to $34.80, a 50.4% drop, reflecting market pessimism regarding the company's future prospects.
- Investor Rights Protection: Investors who suffered losses during the class period are encouraged to contact Bragar Eagel & Squire to understand their legal rights, emphasizing the firm's commitment to protecting investor interests, which may also impact the company's future investment appeal.
See More
Corcept Therapeutics Shareholder Class Action Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that April 21, 2026, is the critical deadline to apply as Lead Plaintiff, urging those who suffered losses to submit their claims promptly.
- Concealed FDA Warnings: The lawsuit alleges that Corcept failed to disclose significant facts regarding its lead drug candidate, relacorilant, during communications with the FDA, misleading investors about the drug's approval prospects.
- Market Crash Impact: Following the announcement of receiving a Complete Response Letter (CRL) from the FDA on December 31, 2025, Corcept's stock plummeted from $70.20 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting severe market disappointment.
- Information Gap Allegations: The complaint asserts that Corcept's management was aware of the clinical data's flaws yet continued to project optimism about approval, creating a significant information gap that may have led to substantial investor losses.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Litigation Timeline: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, or risk losing their right to compensation.
- Fee Structure: Investors participating in the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, allowing them to seek legal recourse without financial burden.
- Case Background: The lawsuit alleges that throughout the class period, Corcept misrepresented the strength of clinical trials for its drug relacorilant, claiming robust support for its NDA, while the FDA had raised significant concerns about the clinical evidence, exposing investors to substantial risks.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its extensive experience and success in this field.
See More
Multiple Companies Face Class Action Lawsuits
- PayPal Lawsuit Overview: From February 2024 to February 2026, PayPal is accused of overstating its ability to execute business initiatives, misleading investors about its prospects, with a lead plaintiff motion deadline set for April 20, 2026.
- NuScale Power Risk Disclosure: During the period from May to November 2025, NuScale Power allegedly failed to disclose significant risks associated with its nuclear projects, prompting investors to act by April 20, 2026, indicating a loss of confidence in the company's future.
- Corcept Therapeutics Regulatory Issues: Between October 2024 and December 2025, Corcept is accused of not disclosing FDA concerns regarding the effectiveness assessment of its drug, misleading investors about its business outlook, with a lead plaintiff motion deadline of April 21, 2026.
- Navan, Inc. IPO Controversy: Navan is accused of failing to disclose a 39% increase in sales and marketing expenses during its 2025 IPO, negatively impacting its revenue and market performance, with a lead plaintiff motion deadline of April 24, 2026.
See More
Class Action Filed Against Corcept Therapeutics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Corcept Therapeutics, aiming to recover damages for investors who purchased securities between October 31, 2024, and December 30, 2025, highlighting serious concerns over the company's potential risks.
- False Statements Allegations: The complaint alleges that the company made materially false statements regarding the strength of clinical trials, claiming they provided “powerful support” for the New Drug Application, while the FDA expressed concerns about the adequacy of clinical evidence, potentially jeopardizing future drug approvals.
- Misleading Regulatory Outlook: The lawsuit points out that Corcept executives falsely conveyed confidence in their regulatory prospects by claiming smooth communication with the FDA, despite repeated concerns raised by the agency regarding the clinical evidence supporting the NDA, undermining investor confidence in the company's future.
- Investor Rights Protection: Bronstein, Gewirtz & Grossman, LLC offers risk-free legal services, promising to charge fees only upon successful recovery, ensuring that investors facing losses can receive legal support to uphold market integrity.
See More
CORT Investors Urged to Act Before April 21 Deadline in Class Action
- Critical Deadline: Hagens Berman reminds investors in Corcept Therapeutics (NASDAQ:CORT) that the deadline to apply as Lead Plaintiff in the securities class action for losses incurred between October 31, 2024, and December 30, 2025, is April 21, 2026, urging prompt submission of loss information to safeguard their rights.
- Allegations Overview: The lawsuit alleges that Corcept concealed significant information regarding its lead drug candidate, relacorilant, as the company publicly emphasized its potential approval while failing to disclose management's private expectations of failure, misleading investors in the process.
- Information Gap: Reed Kathrein, a partner at Hagens Berman, highlighted that the case reveals a
See More
Corcept Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Corcept in the Northern District of California on behalf of investors who purchased shares between October 31, 2024, and December 30, 2025, highlighting significant legal risks and potential liabilities for the company.
- FDA Approval Risks: The lawsuit alleges that Corcept misrepresented the clinical trial results of relacorilant, claiming it provided “powerful support” for FDA approval, while in reality, the FDA raised concerns about the adequacy of clinical evidence, which could undermine the company's credibility and shareholder confidence.
- Stock Price Plunge: Following the announcement of a Complete Response Letter from the FDA on December 31, 2025, Corcept's stock price plummeted from $70.20 to $34.80, a 50.4% drop, reflecting market pessimism regarding the company's future prospects.
- Investor Rights Protection: Investors who suffered losses during the class period are encouraged to contact Bragar Eagel & Squire to understand their legal rights, emphasizing the firm's commitment to protecting investor interests, which may also impact the company's future investment appeal.
See More
Corcept Therapeutics Shareholder Class Action Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that April 21, 2026, is the critical deadline to apply as Lead Plaintiff, urging those who suffered losses to submit their claims promptly.
- Concealed FDA Warnings: The lawsuit alleges that Corcept failed to disclose significant facts regarding its lead drug candidate, relacorilant, during communications with the FDA, misleading investors about the drug's approval prospects.
- Market Crash Impact: Following the announcement of receiving a Complete Response Letter (CRL) from the FDA on December 31, 2025, Corcept's stock plummeted from $70.20 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting severe market disappointment.
- Information Gap Allegations: The complaint asserts that Corcept's management was aware of the clinical data's flaws yet continued to project optimism about approval, creating a significant information gap that may have led to substantial investor losses.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Litigation Timeline: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, or risk losing their right to compensation.
- Fee Structure: Investors participating in the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, allowing them to seek legal recourse without financial burden.
- Case Background: The lawsuit alleges that throughout the class period, Corcept misrepresented the strength of clinical trials for its drug relacorilant, claiming robust support for its NDA, while the FDA had raised significant concerns about the clinical evidence, exposing investors to substantial risks.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its extensive experience and success in this field.
See More
Multiple Companies Face Class Action Lawsuits
- PayPal Lawsuit Overview: From February 2024 to February 2026, PayPal is accused of overstating its ability to execute business initiatives, misleading investors about its prospects, with a lead plaintiff motion deadline set for April 20, 2026.
- NuScale Power Risk Disclosure: During the period from May to November 2025, NuScale Power allegedly failed to disclose significant risks associated with its nuclear projects, prompting investors to act by April 20, 2026, indicating a loss of confidence in the company's future.
- Corcept Therapeutics Regulatory Issues: Between October 2024 and December 2025, Corcept is accused of not disclosing FDA concerns regarding the effectiveness assessment of its drug, misleading investors about its business outlook, with a lead plaintiff motion deadline of April 21, 2026.
- Navan, Inc. IPO Controversy: Navan is accused of failing to disclose a 39% increase in sales and marketing expenses during its 2025 IPO, negatively impacting its revenue and market performance, with a lead plaintiff motion deadline of April 24, 2026.
See More
Class Action Filed Against Corcept Therapeutics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Corcept Therapeutics, aiming to recover damages for investors who purchased securities between October 31, 2024, and December 30, 2025, highlighting serious concerns over the company's potential risks.
- False Statements Allegations: The complaint alleges that the company made materially false statements regarding the strength of clinical trials, claiming they provided “powerful support” for the New Drug Application, while the FDA expressed concerns about the adequacy of clinical evidence, potentially jeopardizing future drug approvals.
- Misleading Regulatory Outlook: The lawsuit points out that Corcept executives falsely conveyed confidence in their regulatory prospects by claiming smooth communication with the FDA, despite repeated concerns raised by the agency regarding the clinical evidence supporting the NDA, undermining investor confidence in the company's future.
- Investor Rights Protection: Bronstein, Gewirtz & Grossman, LLC offers risk-free legal services, promising to charge fees only upon successful recovery, ensuring that investors facing losses can receive legal support to uphold market integrity.
See More
